ライフサイエンスコーパス: hypermethylation

1 ular features were unexplained by LS or MLH1-hypermethylation.

2 on, reduced CTCF binding, and Txnip promoter hypermethylation.

3 cts the different modes of cancer CpG island hypermethylation.

4 nocortical tissues, which is a result of CpG hypermethylation.

5 pressed genes (458) and miRNA (0) and genome hypermethylation.

6 hose repressed by CNOT3 binding and promoter hypermethylation.

7 TGCTs show focal recurrent imprinted domain hypermethylation.

8 loss of GPC5 expression was regulated by its hypermethylation.

9 ation punctuated by regions of glia-specific hypermethylation.

10 correlated better with gene expression than hypermethylation.

11 histone demethylases, to cause broad histone hypermethylation.

12 factors that prevent gene repression and DNA hypermethylation.

13 ating activity, resulting in whole-blood DNA hypermethylation.

14 ched peripheral blood of patients with tumor hypermethylation.

15 s, but in cancer a proportion are subject to hypermethylation.

16 pecific loci by somatic mutation(3,4) or DNA hypermethylation(5) results in the loss of loop anchors

17 lecular level, it results in progressive DNA hypermethylation across domains marked by H3K27me3 and b

18 demonstrated that miR-34A was inactivated by hypermethylation across many histologic types of primary

19 The hypermethylation almost exclusively occurred in regions

20 ation-induced epigenetic alterations and DNA hypermethylation alterations observed in inflammation-in

21 ity, including mutations that lead to 6-fold hypermethylation and 3-fold hypomethylation of the human

22 or maximally reversing abnormal promoter DNA hypermethylation and associated gene silencing to reexpr

23 about the association between MGMT promoter hypermethylation and breast and gynecologic cancers.

24 etic landscape of cancer includes both focal hypermethylation and broader hypomethylation in a genome

25 B1 and RAB25 are downregulated with promoter hypermethylation and CA9 is upregulated with promoter hy

26 r, H19-deficient pre-HSCs displayed promoter hypermethylation and concomitant downregulation of sever

27 base domains defined by gene activation, CpG hypermethylation and depletion of Polycomb-mediated H3K2

28 esults in DNMT3b induction and MEG3 promoter hypermethylation and expression inhibition, further redu

29 As evidence exists for compounding hypermethylation and gene silencing of hemizygous tumor

30 Upon excluding patients with MLH1 promoter hypermethylation and germline mutations, biallelic somat

31 IDH2-R172K mutation results in H3K9 hypermethylation and impaired accessibility at myogenic

32 arate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiat

33 pigenetics of the parental tumour, including hypermethylation and insulator defects.

34 l application also inhibited UVB-induced DNA hypermethylation and its elevation of the levels of TET

35 These genes are silenced, predominantly by hypermethylation and less frequently by mutations, and d

36 interactions often occurs coincidently with hypermethylation and loss of ER binding.

37 gene showing inverse correlation between DNA hypermethylation and mRNA downregulation.

38 kdown of the Fos ecRNA locus results in gene hypermethylation and mRNA silencing, and hippocampal exp

39 ly, the profibrotic factor TGF-beta1 induced hypermethylation and repression of erythropoietin in per

40 d a novel epigenomic subtype associated with hypermethylation and somatic mutations in TET2, DNMT3B,

41 BRCA1 promoter hypermethylation and the BRCAness phenotype of BC cell l

42 e DNA methyltransferase DNMT3B, resulting in hypermethylation and transcriptional silencing.

43 nch syndrome, 2 of 10 (20%) tumors with MLH1 hypermethylation, and 12 of 78 (15%) tumors with microsa

44 icient by IHC of which 83/132 (63%) had MLH1-hypermethylation, and 16/49 (33%) of the remaining patie

45 ine or Dnmt1-siRNA), prevented Mfn2 and Mlh1 hypermethylation, and ameliorated retinal dysfunction an

46 Microsatellite instability, MLH1 promoter hypermethylation, and germline testing of additional gen

47 by HCCs promotes phospholipid formation, DNA hypermethylation, and hepatocyte proliferation.

48 loss of DNA methylation and CpG island (CGI) hypermethylation are key epigenomic aberrations in cance

49 DNA methyltransferases and erythropoietin hypermethylation are upregulated in myofibroblasts.

50 TPMs, further supporting the utility of THOR hypermethylation as a prognostic biomarker.

51 At TSGs, CHD4 retention helps maintain DNA hypermethylation-associated transcriptional silencing.

52 Hypermethylation associates with enhancer silencing.

53 Methylome analysis revealed hypermethylation at a distal CpG island (CGI) near the H

54 e show that human IDH mutant gliomas exhibit hypermethylation at cohesin and CCCTC-binding factor (CT

55 e oxytocin signaling pathway induced by OXTR hypermethylation at CpG 5,6 leads to atypical developmen

56 Several IMs exhibited hypermethylation at DNA methylation valleys; however, IM

57 poxia-induced loss of TET activity increases hypermethylation at gene promoters in vitro.

58 PSCs harboring abnormal hypermethylation at ICRs of the Dlk1-Gtl2-Dio3 imprintin

59 X1 in HCC was attributed to a combination of hypermethylation at its promoter as well as histone modi

60 umber of CpG islands (CGIs) resulting in CGI hypermethylation at key decidualisation genes.

61 latin resistance was associated with loss of hypermethylation at several CpG sites primarily localize

62 ethylator phenotypes (CIMPs), defined as DNA hypermethylation at specific CpG islands in subsets of t

63 Here we show that DNA hypermethylation at the ASNS promoter prevents its trans

64 f DNMT3B in TKO hESCs partially reverses the hypermethylation at the PAX6 promoter and improves diffe

65 tin immunoprecipitation assay confirmed that hypermethylation at the promoter IV region of CIITA is m

66 repressive chromatin marks and aberrant DNA hypermethylation at TSSs in combination with MYC network

67 We identified 25 loci where rare hypermethylation coincided with the presence of an unsta

68 BRCA1 hypermethylation confers an HRD, immune cell type, genom

69 Deletions, mutations and promoter DNA hypermethylation convergently impacted Wnt signaling, Po

70 erasure, NSEs harbor a malignancy-associated hypermethylation core, akin to that of a diverse cancer

71 our findings provide evidence that ODC1 gene hypermethylation could be a starting point for the onset

72 2, and SLC16A5) was associated with promoter hypermethylation, decreased chromatin accessibility, and

73 owth factor beta treatment induced gene-body hypermethylation, dissociation of DNMT1 from the promote

74 eaves at three developmental stages revealed hypermethylation during leaf senescence in dml3 compared

75 fine a fumaric acid ester treatment-specific hypermethylation effect on microRNA MIR-21, which is cri

76 This hypermethylation effect was attributed to the subpopulat

77 Additionally, THOR hypermethylation, either independently or along with TPM

78 differential MGMT methylation profiles, MGMT-hypermethylation enhanced genetic and phenotypic plastic

79 Our data suggest that up to half of hypermethylation events are due to hypoxia, with these e

80 Age-associated hypo- and hypermethylation events occur at distinct regulatory fea

81 ariations, most often recognized as promoter hypermethylation events that lead to gene silencing, are

82 , while Dnmt1 overexpression or Arx enhancer hypermethylation favored beta cell production.

83 deficient tumours unexplained by LS or MLH1-hypermethylation had somatic MMR mutations.

84 n inhibitor of DNA methyltransferase and DNA hypermethylation, has shown treatment efficacy against m

85 Enhancers showed global hypermethylation, however commonly hypomethylated enhanc

86 quently, Tet1 and Tet2 deletion led to Foxp3 hypermethylation, impaired Treg cell differentiation and

87 investigated the frequency of BRCA1 promoter hypermethylation in 237 triple-negative breast cancers (

88 vealed frequent (>45%) cancer-associated DNA hypermethylation in 9 of 11 (82%) tumor types screened.

89 Specifically, we identify widespread hypermethylation in a network of face- and voice-associa

90 pressor gene frequently silenced by promoter hypermethylation in all major solid cancers.

91 IDH2, and CEBPA were strongly linked to DNA hypermethylation in AML using a novel integrative analys

92 understanding of gene silencing by promoter hypermethylation in anal carcinogenesis is needed.

93 DS fetal cortices and observed a significant hypermethylation in approximately 4% of probes in the DS

94 on in peripheral and mucosal tissues and DNA hypermethylation in CD patients requiring surgical inter

95 ffect was mediated by BBP-induced global DNA hypermethylation in CD4(+) T cells of the offspring beca

96 of GULP1 was associated with GULP1 promoter hypermethylation in cell lines and primary tumors, and a

97 and superenhancers, affected by histone H3K4 hypermethylation in disease cases.

98 Global hypomethylation and local hypermethylation in DNA are hallmarks of aging but it is

99 Bisulfite sequencing revealed aberrant hypermethylation in exon 1 of XYLT1, always in trans wit

100 d the expression of CIITA/MHC-II by inducing hypermethylation in histone H3 lysine 9 (H3K9me2/3).

101 oxidative stress, suggesting the role of DNA hypermethylation in inactivation of MSH2 expression and

102 role of aging-like spontaneous promoter DNA hypermethylation in initiating tumorigenesis.

103 Interestingly, we further observed promoter hypermethylation in key overexpressed genes and correspo

104 pressing histone modifications and resembled hypermethylation in liver cancer.

105 1 expression, and the entire locus underwent hypermethylation in LUAD, leading to loss of expression.

106 We demonstrate that cg06690548 hypermethylation in PD is associated with down-regulatio

107 ic hypomethylation and focal allele-specific hypermethylation in poised chromatin.

108 ns of aberrant hypomethylation or CpG island hypermethylation in specific cancer types.

109 genome-wide repetitive LINE-1 elements, and hypermethylation in specific promoter regions of single-

110 Both 5hmC in wild-type (WT) genomes and DNA hypermethylation in TET-deficient genomes are largely co

111 Hypermethylation in the 3'-protein-phosphatase-1G (PPM1G

112 the effect of a putative persistent Ddo gene hypermethylation in the brain, we used Ddo knock-out mic

113 Anal hrHPV and promoter hypermethylation in the cervix show promise as biomarker

114 at LTF expression is silenced via CpG island hypermethylation in the early stages of prostate tumorig

115 ls owing to an increased DNA copy number and hypermethylation in the H19 promoter of the IGF2 gene.

116 e findings provide initial evidence for OXTR hypermethylation in the intron area as a potential bioma

117 Recently we identified a hypermethylation in the long noncoding RNA 299 (LINC0029

118 ealed a significant excess of age-associated hypermethylation in the rDNA relative to other segments

119 hylated in gametes had already undergone CHH hypermethylation in the SAM.

120 tiple malignancies by suppressing epigenetic hypermethylation in tumor cells.

121 ionally, IDH(mut) caused a greater degree of hypermethylation in undifferentiated neural progenitor c

122 DNA methyltransferase 1 (DNMT1) and a global hypermethylation in vascular endothelium subjected to di

123 Frequent hypermethylation including that of CDH1 in AM increased

124 isulfite sequencing confirmed dense promoter hypermethylation indicative of silencing in multiple mal

125 ighly relevant ccRCC cell line that displays hypermethylation-induced UQCRH extinction.

126 ced Dnmt3b expression induced widespread DNA hypermethylation inMyc-Bcl2-induced leukemias, preferent

127 T3A(R882), while DNMT3A-dependent CpG island hypermethylation is a consequence of AML progression.

128 Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, wheth

129 Thus, we propose that THOR hypermethylation is a prevalent telomerase-activating me

130 So, promoter hypermethylation is associated with down-regulation of C

131 ysis of genome sequence data showed that the hypermethylation is associated with expansion of a GGC r

132 MGMT promoter hypermethylation is currently the only known biomarker f

133 DNA 5mC hypermethylation is dispensable while H3K9 hypermethylat

134 ionally, we observe that promoter CpG island hypermethylation is not restricted solely to emerging na

135 C hypermethylation is dispensable while H3K9 hypermethylation is required for this differentiation bl

136 At the epigenetic level, global hypermethylation is the dominant process.

137 We demonstrate that BRCA1 promoter hypermethylation is twice as frequent as BRCA1 pathogeni

138 e changes are often correlated with promoter hypermethylation, leading to decreased expression of tum

139 ntly reported that HPV E7-dependent promoter hypermethylation leads to downregulation of the chemokin

140 corneal endothelial cells in which miR-199B hypermethylation leads to miR-199b-5p downregulation and

141 ypomethylation-high expression genes and 168 hypermethylation-low expression genes were identified at

142 n a DNMT3A-dependent manner, suggesting that hypermethylation may be a response to, rather than a cau

143 Hypermethylation may be an early event in tumor developm

144 dy suggests that loss of UQCRH expression by hypermethylation may promote kidney carcinogenesis throu

145 miRNA silencing by promoter hypermethylation may represent a mechanism by which lung

146 ith healthy controls implying that LINC00299 hypermethylation may serve as a circulating biomarker fo

147 f global hypomethylation coupled to regional hypermethylation observed in diverse cancer genomes, and

148 A methylation changes, including significant hypermethylation, occur more frequently in early colonic

149 ts and observed widespread aberrant cytosine hypermethylation occurring preferentially outside CpG is

150 dicated that 5mC changes are localized, with hypermethylation occurring within a background of genome

151 Constitutional hypermethylation of 1 allele throughout the soma (consti

152 53, RB1, CYLD, AR) and epigenomic (hypo- and hypermethylation of 20 differential sites) alterations a

153 Gene-specific hypermethylation of 25-hydroxylase, 1-alpha-hydroxylase,

154 es with enhanced DCL4(NLS) expression, while hypermethylation of a DCL4 transgene causes a reduction

155 but not E6 transfection of NOK cells led to hypermethylation of a positively correlated CpG island w

156 CRPC-NE-associated epigenetic changes (e.g., hypermethylation of ASXL3 and SPDEF; hypomethylation of

157 les, and demonstrate that the conjunction of hypermethylation of bivalent chromatin and up-regulation

158 that can identify cancer samples solely from hypermethylation of bivalent chromatin.

159 oring the cancer DNA methylome, with gradual hypermethylation of bivalent developmental genes.

160 For example, we observed promoter hypermethylation of BRCA1 and LDLR at population frequen

161 genomic-imprint and DPPA3 erasure, recurrent hypermethylation of cancer-associated targets, and subty

162 eride concentrations (MR, P=1.5x10(-14)).and hypermethylation of cg02079413 (SNORA54; NAP1L4) was ass

163 Relative hypermethylation of cg04256470 (688 bases upstream of CO

164 For example, hypermethylation of cg11250194 (FADS2) was associated wi

165 Hypermethylation of cg18181703 (SOCS3) was associated wi

166 Aberrant hypermethylation of CpG islands (CGI) in human tumors oc

167 Aberrant hypermethylation of CpG islands in the promoter region o

168 Hypermethylation of CpG islands in the RASSF1A promoter

169 ecifically, we show that mutant PPM1D drives hypermethylation of CpG islands throughout the genome an

170 activity of mutant IDH2 proteins results in hypermethylation of DNA and histones, leading to blocked

171 epigenetic program that is characterized by hypermethylation of DNA methylation valleys that are cha

172 ce and distribution of 5hmC, which prevented hypermethylation of DNA, and for regulation of the B cel

173 Hypermethylation of FAM19A4 and/or microRNA124-2 was fou

174 east tissue, parity has been associated with hypermethylation of FOXA1, a pioneer transcription facto

175 om patients with TB are characterized by DNA hypermethylation of genes critical to mycobacterial immu

176 We identified promoter hypermethylation of genes that contain neoantigenic muta

177 We report hypo- and hypermethylation of genes within functional categories r

178 pression by ASC adipokines leads to promoter hypermethylation of GJA1 and related genes in the endome

179 an endometrial cancer cohort (n = 141), DNA hypermethylation of GJA1 and related loci TJP2 and PRKCA

180 These results suggest that the age-dependent hypermethylation of GRSF1 reduces its expression, which

181 EAP1-NRF2 signaling in UCB and that promoter hypermethylation of GULP1 is a potential mechanism of GU

182 deficient diet reduced proliferation and DNA hypermethylation of hepatocytes and HCC cells, and the C

183 Moreover, hypermethylation of HES4 promoter sequences was striking

184 lysine demethylase KDM4B results in aberrant hypermethylation of histone 3 lysine 9 (H3K9) at loci su

185 E methylation accumulate SAM, which leads to hypermethylation of histones and the major phosphatase P

186 DNA methylome analysis revealed excessive hypermethylation of iCCA, affecting primarily the bivale

187 SKIP gene (SPHKAP) expression is silenced by hypermethylation of its promoter in acute myeloid leukem

188 or gene was shown to be often inactivated by hypermethylation of its promoter region.

189 f TFF2 to be down-regulated in human PDAC by hypermethylation of its promoter.

190 ition of progesterone signaling is caused by hypermethylation of its receptor Pgr by Notch1 overexpre

191 Germline hypermethylation of KLLN, a gene uncovered well after th

192 of good glycemia had no beneficial effect on hypermethylation of Mfn2 and Mlh1 and retinal function (

193 a-analysis to assess the association between hypermethylation of MGMT promoter and the risk of breast

194 in the level of histone H3 acetylation, and hypermethylation of MSH2 promoter were also observed in

195 We show that hypermethylation of p16/Ink4a and p19/Arf in CNT- and as

196 lation of the TP63N transcriptional network, hypermethylation of pancreatic endodermal cell-fate dete

197 h differential expression of ANO1, we showed hypermethylation of positively correlated CpG islands po

198 And small shift of hypermethylation of previously hypomethylated region was

199 TET2 reduction results in hypermethylation of promoter CGIs and enhancers in loci

200 y global hypomethylation in conjunction with hypermethylation of promoter CpG islands; these changes

201 Aberrant DNA hypermethylation of promoter of tumor suppressor genes i

202 e regulators of STAT3, including by promoter hypermethylation of PTPRT.

203 of ocular tissue-specification and described hypermethylation of retinal transcription factors (i.e.,

204 Clinically, hypermethylation of REX1 was closely associated with neo

205 Hypermethylation of selected CpG sites was confirmed in

206 n (r = -0.96; P < 10-8) and characterized by hypermethylation of targets of the polycomb repressor co

207 bundance of 24-nt siRNAs was associated with hypermethylation of TEs and gene promoters, with influen

208 Hypermethylation of the ANO1 promoter was strongly corre

209 oral keratinocytes (NOK) were used to induce hypermethylation of the ANO1 promoter.

210 Bisulfite sequencing confirmed hypermethylation of the APEX1 promoter region in HD cell

211 None of the studied BC cell lines presented hypermethylation of the BRCA1 promoter region.

212 lated region (UTR) hypomethylation and 3'UTR hypermethylation of the cellular epitranscriptome, regul

213 AIE exposure was associated with hypermethylation of the COMT promoter at a conserved CpG

214 leads to suppression of the E2F1 pathway and hypermethylation of the CpG sites at miR-184 promoter, r

215 Hypermethylation of the DMR inhibited recruitment of PR

216 Specifically, hypermethylation of the DPH1 gene, encoding a key enzyme

217 omatal lineage cells, which is linked to DNA hypermethylation of the ERECTA family genes, including E

218 cumulation of 2-hydroxyglutarate resulted in hypermethylation of the Foxp3 gene locus and inhibited F

219 Here, we examined the role of hypermethylation of the G-rich sequence factor 1 (GRSF1)

220 Analyses showed a significant hypermethylation of the Gata3 promoter detectable only i

221 We also found hypermethylation of the H19 locus, a known driver of Wil

222 The DNA hypermethylation of the IL-12/IFN-gamma pathway was asso

223 and found that the patients with TB have DNA hypermethylation of the IL-2/STAT5, TNF/NF-kappaB, and I

224 ink between fumaric acid ester treatment and hypermethylation of the MIR-21 locus in both CD4 and CD8

225 ; several lipid metabolism mRNAs; coincident hypermethylation of the PPARgamma2 proximal promoter; an

226 Hypermethylation of the promoters of tumour suppressor g

227 Persistent abnormal hypermethylation of the SRY gene was observed together w

228 Hypermethylation of the TET2 gene down-regulated its tra

229 displays a schizophrenia-like phenotype and hypermethylation of the transcription factor, Sp5.

230 sis behind one such predictive model linking hypermethylation of the UBB ubiquitin gene to a dependen

231 The DNA hypermethylation of these pathways was associated with d

232 moter activity regardless of TPM status, and hypermethylation of THOR counteracted this repressive fu

233 We observed that hypermethylation of tumor suppressor genes is a frequent

234 Exposing cancer cells to metformin leads to hypermethylation of tumor-promoting pathway genes and co

235 howed that PSTVd infection promotes a strong hypermethylation of TYLCSV DNA, thus supporting a mechan

236 tic effects of depressive disorder and NR3C1 hypermethylation on long-term cardiac outcomes in ACS we

237 CA2, BRCA1 promoter hypermethylation, RAD51C hypermethylation or biallelic loss of PALB2.

238 tellite instability not attributable to MLH1 hypermethylation or germline mutations contain 2 or more

239 tly, a small subset of genes that showed DNA hypermethylation or hypomethylation was correlated with

240 reduced BRCA1 transcription, due to promoter hypermethylation or loss of the BRCA1 transcriptional re

241 Lynch syndrome while 106 (9.0%) have somatic hypermethylation or mutations in the mismatch repair gen

242 r carcinomas (HCC) exhibit distinct promoter hypermethylation patterns, but the epigenetic regulation

243 ydroxyglutarate (2HG) and a CpG island (CGI) hypermethylation phenotype (G-CIMP).

244 (R)-2-hydroxyglutarate (2-HG), leading to a hypermethylation phenotype that dysregulates hematopoiet

245 leukemia (AML) and are associated with a DNA hypermethylation phenotype.

246 unD was epigenetically regulated by promoter hypermethylation, post-translational modification of his

247 NR3C1 hypermethylation predicted worse long-term prognosis of

248 pomethylation profile with a selective small hypermethylation profile located in open-sea regions in

249 Regions implicated in the hypermethylation profile were involved in Notch signalli

250 with a genome-wide tendency for neuronal CpG-hypermethylation punctuated by regions of glia-specific

251 tic mutations of BRCA1/BRCA2, BRCA1 promoter hypermethylation, RAD51C hypermethylation or biallelic l

252 Following the initial global wave of hypermethylation, rare decay events of maintenance methy

253 ither chromatin reader activity reverses DNA hypermethylation, reactivates epigenetically silenced tu

254 rived neurotrophic factor), leading to their hypermethylation, reduced expression, as well as the beh

255 he tumor suppressor gene RASSF1A by promoter hypermethylation represents a key event underlying the i

256 ulated by allelic loss and site-specific DNA hypermethylation, respectively.

257 ll lines, we demonstrated that aberrant ASNS hypermethylation sensitizes subsets of gastric and hepat

258 tifies a myeloid-specific smoking-associated hypermethylation signature enriched for DNase Hypersensi

259 lon-derived organoids, we show that promoter hypermethylation spontaneously arises in cells mimicking

260 Mismatch repair (MMR), IHC, and promoter hypermethylation status of MLH1 (MLH1ph) in microsatelli

261 Decreased hOCT1 mRNA correlated with hypermethylation status of the SLC22A1 promoter.

262 on is silenced in prostate tumorigenesis via hypermethylation, supporting a role for LTF as a prostat

263 mors harboring TERT promoter mutation and/or hypermethylation than those without either aberration (P

264 nephritis via a mechanism involving promoter hypermethylation that is associated with Ifitm3 repressi

265 s with wild-type DNMT3A displayed CpG island hypermethylation, this change was not associated with ge

266 on in tumors was 10 times more frequent than hypermethylation, three times more frequent in CLL than

267 ukemogenesis showed much less pronounced DNA hypermethylation upon Dnmt3b expression.

268 tent and targets of IDH(mut)-induced genomic hypermethylation vary greatly according to the cellular

269 on was attributed to nickel-induced promoter hypermethylation via elevating DNMT3b expression, wherea

270 Moreover, miR-34A tumor hypermethylation was associated with decreased overall s

271 Significant hypermethylation was confirmed (p < 0.05) following oral

272 Hypermethylation was detectable for all genes in maligna

273 No case of constitutional SDHC promoter hypermethylation was detected.

274 Hypermethylation was enriched at CpG islands marked with

275 Failure of SRY expression due to hypermethylation was further correlated with silencing o

276 Por hypermethylation was not observed after THC injection or

277 Further, significant hypermethylation was observed in promoter DNA region of

278 This hypermethylation was related to clinical symptoms and to

279 utaneous T-cell lymphoma cell line, promoter hypermethylation was shown to downregulate MTAP expressi

280 This meta-analysis indicated that MGMT hypermethylation was significantly associated with the r

281 miR-508-3p down-regulation, due to promoter hypermethylation, was directly correlated with metastati

282 gulated genes linked to promoter or enhancer hypermethylation were identified.

283 e similar to those in mammals, and hypo- and hypermethylation were predictive of increased and decrea

284 CSMD1 deletions or promoter hypermethylation were present in all of the immortal PPO

285 Escape genes showing CH hypermethylation were the only genes with CG-hypomethyla

286 bal hypomethylation but with skewing towards hypermethylation when interrogating gene promoters.

287 i depicted hypomethylation, and 225 depicted hypermethylation, whereas in Monos, 155 hypomethylated l

288 ydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differ

289 d DNMT3B binding is associated with promoter hypermethylation, which precipitates a neural differenti

290 ed hypoxia in mouse breast tumours increases hypermethylation, while restoration of tumour oxygenatio

291 s underwent hypo-hydroxymethylation prior to hypermethylation, while retaining H3K27me3.

292 Subtype 1 was characterized by DNA hypermethylation with a high mutation burden and multipl

293 Skeletal muscle tissue demonstrates global hypermethylation with age.

294 Both groups showed excessive hypermethylation with distinct patterns.

295 suggest a potential association of LINC00299 hypermethylation with TNBC in young women.

296 NAMPT promoter analysis revealed CpG hypermethylation within the dilated human thoracic aorta

297 eparated cell data shows that IBD-associated hypermethylation within the TXK promoter region negative

298 such as global hypomethylation and localized hypermethylation, within the promoters of tumor suppress

299 (hESCs) exhibit prominent bivalent promoter hypermethylation without an overall corresponding decrea

300 These mutations promote hypermethylation, yet it is only a favorable prognostic